Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 7.2 mg in Obesity
NCT05646706Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2023
- Primary completion
- Oct 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
A Phase 3 trial of semaglutide in obesity, sponsored by Novo Nordisk. Started Jan 2023; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05646706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05646706.